---
schema_version: "secwatch.filing_event.v1"
accession: "0001213900-25-051750"
form_type: "8-K"
ticker: "CERO"
cik: "0001870404"
company_name: "CERO THERAPEUTICS HOLDINGS, INC."
filed_at: "2025-06-06T23:59:59+00:00"
generated_at: "2026-05-19T18:39:15.033001+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.45
calibrated_materiality_score: 0.45
confidence: "high"
source: SEC EDGAR
---

# CERo Therapeutics raises ~$750k in Series D financing; first-in-human dosing under way

## Summary
- Gross proceeds from additional closing ~$750k; total Series D up to $8M with $5M previously issued.
- Series D convertible preferred converts to common; additional $2.25M possible at investors' option.
- Proceeds to support clinical development of CAR-T candidate CER-1236, including IND allowances and site activation at MDACC.
- Company reports first-in-human dosing in AML for CER-1236, a TIM-4L-targeted autologous CAR-T.
- CEO Chris Ehrlich cites continued investor support and clinical progress.

## SEC filing metadata
- accession: 0001213900-25-051750
- form_type: 8-K
- ticker: CERO
- cik: 0001870404
- company_name: CERO THERAPEUTICS HOLDINGS, INC.
- filed_at: 2025-06-06T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.45
- calibrated_materiality_score: 0.45
- confidence: high
- sec_items: 3.02, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1870404/000121390025051750/0001213900-25-051750-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1870404/000121390025051750/ea0244845-8k_cero.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001213900-25-051750
- JSON: https://secwatch.observer/filing/0001213900-25-051750.json
- Plain text: https://secwatch.observer/filing/0001213900-25-051750.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.